Downregulation of NCAPD2 can inhibit tumor growth in vivo (74), promote the release of pro-inflammatory factors (75), enhance cell cycle progression and invasive capabilities (76), regulate autophagy (77), and serve as a prognostic biomarker in various cancers (78). The gene discussed is NCAPD2; the disease is cancer.